Negative impact of malignant effusion on osimertinib treatment for non-small cell lung cancer harboring EGFR mutation

3rd-generation epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), including osimertinib, have reasonable efficacy in non–small-cell lung cancers (NSCLC) with EGFR mutations. However, the efficacy of osimertinib in NSCLC patients with fluids, such as pleural, pericardial and abd...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Invest New Drugs
Egile Nagusiak: Kawamura, Takahisa, Kenmotsu, Hirotsugu, Kobayashi, Haruki, Omori, Shota, Nakashima, Kazuhisa, Wakuda, Kazushige, Ono, Akira, Naito, Tateaki, Murakami, Haruyasu, Mori, Keita, Endo, Masahiro, Takahashi, Toshiaki
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Springer US 2019
Gaiak:
Short Report
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6985082/
https://ncbi.nlm.nih.gov/pubmed/31183631
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-019-00808-1
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak